Evolus (NASDAQ:EOLS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $27.00 price target on the stock.

Several other equities research analysts also recently weighed in on the company. Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Tuesday, January 21st.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $14.17 on Wednesday. Evolus has a 1-year low of $9.25 and a 1-year high of $17.82. The business has a 50-day moving average of $12.79 and a 200-day moving average of $14.08. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The company has a market capitalization of $897.26 million, a price-to-earnings ratio of -15.57 and a beta of 1.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tang Capital Management LLC lifted its holdings in Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after buying an additional 150,000 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in Evolus by 10.8% during the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock worth $34,557,000 after buying an additional 305,300 shares during the last quarter. Caligan Partners LP lifted its holdings in Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after buying an additional 498,900 shares during the last quarter. Millennium Management LLC lifted its holdings in Evolus by 29.1% during the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock worth $15,107,000 after buying an additional 308,753 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its holdings in Evolus by 30.9% during the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock worth $14,217,000 after buying an additional 304,065 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.